FDA Approves Ovarian Cancer Treatment Based on New Biomarker

On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula) to include an additional group of patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: those whose cancer has progressed despite treatment with at least three different cytotoxic chemotherapy regimens and tests positive for a new biomarker called homologous recombination deficiency (HRD).

Read More